In a nutshell This phase II clinical trial tested whether a new drug, entinostat, can work in concert with exemestane (a hormone therapy drug), to fight breast cancer that no longer responds to hormone therapy alone. Some background Some breast cancers need estrogen (a female sex hormone) to grow. These breast cancer cells respond to estrogen via...
Read MoreMenopausal status-Postmenopausal Posts on Medivizor
Phase 3 clinical trial evaluating the safety and efficacy of adding everolimus to exemestane therapy in patients with hormone receptor-positive advanced breast cancer
In a nutshell This phase 3 clinical trial tested whether everolimus (a non-hormonal treatment) added to hormone therapy with exemestane improved survival in patients with advanced breast cancer (BCa). Some background Some BCa are fueled by female sex hormones (estrogen or progesterone) that help them grow. These types of cancer are called...
Read MoreCombination of Anastrozole and Fulvestrant therapy in hormone receptor positive metastatic breast cancer
In a nutshell This study compared the effect of two regimens for hormone-positive, metastatic breast cancer on disease progression and survival: a combination of two drugs, namely anastrozole (Arimidex) and fulvestrant (Faslodex), versus anastrozole alone. Some background Breast cancers often require estrogen (the female sex...
Read MoreBenefits of postoperative chemotherapy vary according to breast cancer type
In a nutshell This study questioned the benefit of adding chemotherapy to postoperative hormonal treatment in the case of lobular breast cancer. Their findings were that chemotherapy seems to offer no additional beneficial effects in women with lobular breast cancer receiving hormonal therapy. Some background There are two main types of breast...
Read More